Importantly, knocking down MAOA expression impeded tumor growth of both androgen-dependent LNCaP cells and castration-resistant C4-2BENZR cells (a LNCaP-derived CRPC subline with acquired resistance to the antiandrogen drug enzalutamide) (31), indicating that MAOA is a valid target for AR-positive PC cells regardless of cellular reliance on androgens. The gene discussed is MAOA; the disease is neoplasm.